Dorayshield recently achieved another success in its foreign trade business – the successful delivery of a 1cc tungsten alloy syringe shield to a Belgian medical equipment supplier. This successful order not only marks a breakthrough for the company's low-dose medical radiation protection products in the Western European market but also demonstrates the company's expertise in the international nuclear medicine protection field, building a new bridge for deepening China-Belgium medical equipment trade cooperation.
The 1cc tungsten syringe shield is a critical piece of protective equipment used in nuclear medicine clinical procedures. It's primarily used to shield medical personnel from scattered radiation when injecting radiopharmaceuticals with a 1cc syringe. Compared to traditional lead shields, this product, made from high-density tungsten alloy, is approximately 30% lighter while maintaining the same shielding effectiveness, making it easier for medical personnel to operate. Furthermore, its precision-polished interior allows for clear viewing of the medication scale, preventing blurred vision that could affect injection accuracy. It also eliminates the risk of lead contamination and fully complies with environmental standards in modern medicine. The Belgian healthcare system, renowned for its high standards and stringent compliance, places extremely high demands on the performance, safety, and environmental performance of medical protective products. The medical equipment supplier involved in this collaboration is deeply embedded in the local nuclear medicine equipment market, with products distributed throughout the nuclear medicine departments of numerous Belgian hospitals. They maintain stringent standards for the shield's shielding efficiency and ease of use. To meet demand, Dorayshield implements strict control throughout the entire process, from raw material procurement to production testing: selecting tungsten alloy raw materials with a purity of 99.9%, using CNC machining to ensure that the inner diameter of the shield precisely fits a 1cc syringe, and entrusting a third-party testing agency to conduct radiation shielding performance tests. Ultimately, Dorayshield won customer recognition with its excellent quality and compliance.
For Dorayshield, this export to Belgium represents more than just a successful order; it also strengthens the company's international competitiveness in low-dose medical radiation protection. Going forward, the company will leverage this collaboration to continuously monitor the development needs of the nuclear medicine field in Belgium and Western Europe, increase its R&D investment in low-dose protection products, and launch more customized solutions for diverse clinical scenarios. Furthermore, through participation in European medical equipment exhibitions and deepening collaboration with local distributors, the company aims to expand its high-quality protection products to Western European medical institutions, contributing to the safety upgrade of global nuclear medicine clinical operations and driving higher-quality growth in its foreign trade business.
